about
An Antibody That Locks HER3 in the Inactive Conformation Inhibits Tumor Growth Driven by HER2 or NeuregulinDirect binding of the EGF-like domain of neuregulin-1 to integrins ({alpha}v{beta}3 and {alpha}6{beta}4) is involved in neuregulin-1/ErbB signalingSustained high levels of neuregulin-1 in the longest-lived rodents; a key determinant of rodent longevityTargeting human epidermal growth factor receptor signaling with the neuregulin's heparin-binding domainA genetic screen for anchorage-independent proliferation in mammalian cells identifies a membrane-bound neuregulin.An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activationIdentification of mTORC2 as a necessary component of HRG/ErbB2-dependent cellular transformationERBB3: A potential serum biomarker for early detection and therapeutic target for devil facial tumour 1 (DFT1)Localization of phosphorylated ErbB1-4 and heregulin in colorectal cancerTranscriptome meta-analysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway genes.Transautocrine signaling by membrane neuregulins requires cell surface targeting, which is controlled by multiple domainsIntra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification.HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumorsActivation of multiple ERBB family receptors mediates glioblastoma cancer stem-like cell resistance to EGFR-targeted inhibition.Identification of therapeutic targets in ovarian cancer through active tyrosine kinase profiling.Cucurbitacin I inhibits Rac1 activation in breast cancer cells by a reactive oxygen species-mediated mechanism and independently of Janus tyrosine kinase 2 and P-Rex1.The HER2- and heregulin β1 (HRG)-inducible TNFR superfamily member Fn14 promotes HRG-driven breast cancer cell migration, invasion, and MMP9 expression.Modulation of tissue repair by regeneration enhancer elements.Neuregulin expression in solid tumors: prognostic value and predictive role to anti-HER3 therapies.Emerging role of neuregulin as a modulator of muscle metabolism.Oncogenic function and clinical implications of SLC3A2-NRG1 fusion in invasive mucinous adenocarcinoma of the lungAn heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.Engineering multivalent antibodies to target heregulin-induced HER3 signaling in breast cancer cellsBiological insights into effective and antagonistic combinations of targeted agents with chemotherapy in solid tumors.Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer.HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy.Clinical significance of overexpression of NRG1 and its receptors, HER3 and HER4, in gastric cancer patients.Oncogenic Ras triggers hyperproliferation and impairs polarized colonic morphogenesis by autocrine ErbB3 signaling.Recent Advances in ADAM17 Research: A Promising Target for Cancer and Inflammation.Regulation of the prometastatic neuregulin-MMP13 axis by SRC family kinases: therapeutic implications.Resistance to receptor-blocking therapies primes tumors as targets for HER3-homing nanobiologics.EGFR targeted inhibition resistance: compensatory activation of ERBB family members in glioblastoma cancer stem-like cells promotes proliferation.Neuregulin-1 alleviates Charcot-Marie-Tooth disease in rats.Breast cancer dissemination promoted by a neuregulin-collagenase 3 signalling node.P-Rex1 participates in Neuregulin-ErbB signal transduction and its expression correlates with patient outcome in breast cancer.The immunoglobulin-like domain of neuregulins potentiates ErbB3/HER3 activation and cellular proliferation.
P2860
Q27679463-270D6166-8C80-495C-8027-7953208E4EE7Q28116711-532065E1-B307-4173-BDED-0BBE2A753ABAQ28649598-E722DEBA-8852-42D0-A3AB-6900558C8179Q33553857-887EAC8E-DD3A-4C04-81BD-8E064C9AEC0CQ33644471-9DD5ECDE-3A23-4833-9E59-242E0F0E13F2Q33733313-1F7F5ED7-68F4-4352-B2C5-A6B17E594D38Q33758255-0E4317E4-9FF5-44A5-BAAB-B07575D26DCDQ33772914-47FBCB98-F0E5-4D76-A725-03873BAF8CE7Q34586892-B465C848-5511-4FB2-81E0-1DE00F1FBA8CQ34762165-8E0846FA-BEF6-49C7-9168-AA09EAE5E67BQ35085158-4F363657-A846-4706-BDF8-B74750D32FA4Q35633666-9BE3E145-1DE7-470D-BECA-29FF6B1FA836Q36025680-38C60C04-E4AF-403B-B8C2-E82A35F1187AQ36062158-C51C7B9B-D619-4118-80DD-9A63BBB66D94Q36557500-175F1018-E450-4893-8200-6664406242BCQ36776754-A7F06718-270F-46C2-AEA8-3C1DCBC65202Q36780754-A725532F-EA59-45F1-9B2B-A827A0941DAAQ36832920-43C017CC-F748-403C-B881-211D6A0C190DQ37564335-FF6F6796-750D-467E-9790-D9057C9854D3Q37661237-3BEBEF76-F502-487F-AE3B-EA708DBBC17BQ37688390-377701FD-F77C-4982-A29C-A1B3FAB9542DQ37690880-6427F0B6-5991-4722-AD05-AD64FF139BAAQ37698914-FF8F0245-FF4F-491E-859F-69AE4BCD3D4EQ38171330-E1CB9E82-C135-4E9A-B978-6E728FFE87A1Q38932495-D756A083-C0AA-467C-BA7E-B0B6FAE57A73Q39368710-C06B1338-5C77-4971-95CE-9DF43667FE27Q40176588-45B6BFDE-4B0F-4022-9069-5DC8E79DA43BQ42324659-B481C740-B703-46A3-AFD2-9A7F97028425Q46450905-EF0A72C7-6A04-4F7A-BC57-1F51E9DCA101Q47107645-C0AD07EB-7746-4E2E-984F-79C059EF1705Q47243379-93AAD374-0122-4DA3-9BC8-70DA9820D7D3Q48371427-6208834C-F64D-4865-8686-2594D3717888Q50636102-6DC56654-50FE-4586-B6D6-3E18466CA5BCQ54246808-8926D2FB-DB2E-4FD1-AF6F-86543CA94865Q54403803-E57FB15D-994E-4FD2-AAF8-D57ED0E63917Q55516477-BB4678CA-6C52-4282-BCDC-F20FF39CBF04
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Neuregulins and cancer.
@en
Neuregulins and cancer.
@nl
type
label
Neuregulins and cancer.
@en
Neuregulins and cancer.
@nl
prefLabel
Neuregulins and cancer.
@en
Neuregulins and cancer.
@nl
P50
P1476
Neuregulins and cancer
@en
P2093
Atanasio Pandiella
P304
P356
10.1158/1078-0432.CCR-07-5133
P407
P577
2008-06-01T00:00:00Z